Related Experiment Videos
Hormone replacement therapy in systemic lupus erythematosus
S Kreidstein1, M B Urowitz, D D Gladman
1Centre for Prognosis Studies in the Rheumatic Diseases, The Toronto Hospital, Ontario, Canada.
The Journal of Rheumatology
|February 7, 1998
Summary
Hormone replacement therapy (HRT) did not increase lupus flares in postmenopausal women with systemic lupus erythematosus (SLE). This study found no significant difference in flare rates between HRT users and controls over a 12-month period.
Area of Science:
- Rheumatology
- Endocrinology
- Women's Health
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
- Menopause can present unique challenges for women with SLE.
- Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
Purpose of the Study:
- To determine if HRT use is associated with an increased risk of lupus flares.
- To evaluate the safety of HRT in postmenopausal women with SLE.
Main Methods:
- A case-control study comparing 16 postmenopausal women with SLE on HRT to 32 matched controls.
- Disease flare defined as an increase in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) over 12 months.
- Flare incidence compared using McNemar's test or Mantel-Haenszel test.
Main Results:
- HRT users had a longer disease duration but similar SLEDAI at presentation compared to controls.
- No statistically significant difference in the rate of lupus flares was observed between the HRT group and the control group.
- Control patients were older at diagnosis and presentation.
Conclusions:
- HRT use in postmenopausal women with SLE does not appear to elevate the risk of lupus flares.
- Findings suggest HRT may be a safe option for managing menopausal symptoms in this patient population.
- Further research may explore long-term effects and specific HRT formulations.